应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06872 丹诺医药-B
休市中 11-20 16:08:27
73.300
-1.200
-1.61%
最高
78.800
最低
72.100
成交量
5.11万
今开
76.350
昨收
74.500
日振幅
8.99%
总市值
38.34亿
流通市值
38.34亿
总股本
5,230万
成交额
383.34万
换手率
0.10%
流通股本
5,230万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
港股异动 | 丹诺医药-B(06872)涨近3% 近日与远大生命科学订立独家商业化合作协议补充协议
智通财经 · 11-18
港股异动 | 丹诺医药-B(06872)涨近3% 近日与远大生命科学订立独家商业化合作协议补充协议
港股异动 | 丹诺医药-B(06872.HK)涨近3% 近日与远大生命科学订立独家商业化合作协议补充协议
智通财经 · 11-18
港股异动 | 丹诺医药-B(06872.HK)涨近3% 近日与远大生命科学订立独家商业化合作协议补充协议
丹诺医药-B(06872)与远大生命科学订立独家商业化合作协议补充协议
智通财经 · 11-13
丹诺医药-B(06872)与远大生命科学订立独家商业化合作协议补充协议
丹诺医药-B(06872)与远大生命科学签署补充协议 将TNP-2198中国上市许可里程碑延后至2027年7月31日
公告速递 · 11-13
丹诺医药-B(06872)与远大生命科学签署补充协议 将TNP-2198中国上市许可里程碑延后至2027年7月31日
丹诺医药-B(06872)公布两大核心抗感染新药最新研发进展
公告速递 · 11-12
丹诺医药-B(06872)公布两大核心抗感染新药最新研发进展
丹诺医药-B回购4000股股份,总额约28.09万港元
公告速递 · 11-05
丹诺医药-B回购4000股股份,总额约28.09万港元
丹诺医药-B:11月4日回购5000股,耗资约34.05万港元
公告速递 · 11-04
丹诺医药-B:11月4日回购5000股,耗资约34.05万港元
丹诺医药-B(06872.HK)11月4日斥资34.05万港元回购5000股
智通财经 · 11-04
丹诺医药-B(06872.HK)11月4日斥资34.05万港元回购5000股
丹诺医药-B回购5000股股份,涉资约32.20万港元
公告速递 · 11-03
丹诺医药-B回购5000股股份,涉资约32.20万港元
丹诺医药-B(06872)11月3日斥资32.2万港元回购5000股
智通财经 · 11-03
丹诺医药-B(06872)11月3日斥资32.2万港元回购5000股
港股异动 | 丹诺医药-B(06872)盘中涨超7% TNP-2092优先开发关节腔内注射给药治疗人工关节感染适应症
智通财经 · 11-03
港股异动 | 丹诺医药-B(06872)盘中涨超7% TNP-2092优先开发关节腔内注射给药治疗人工关节感染适应症
丹诺医药-B2026年10月股份变动月报表,股本保持不变
公告速递 · 11-02
丹诺医药-B2026年10月股份变动月报表,股本保持不变
丹诺医药-B(06872):利福喹酮(TNP-2092)优先开发关节腔内注射给药治疗人工关节感染适应症
智通财经网 · 10-30
丹诺医药-B(06872):利福喹酮(TNP-2092)优先开发关节腔内注射给药治疗人工关节感染适应症
丹诺医药-B(06872)将利福喹酮确定为优先开发关节腔内注射治疗人工关节感染核心适应症
公告速递 · 10-30
丹诺医药-B(06872)将利福喹酮确定为优先开发关节腔内注射治疗人工关节感染核心适应症
丹诺医药-B(06872)10月27日斥资约105.32万港元回购约1.12万股
智通财经 · 10-27
丹诺医药-B(06872)10月27日斥资约105.32万港元回购约1.12万股
丹诺医药-B回购11,150股股份,总额约105.32万港元
公告速递 · 10-27
丹诺医药-B回购11,150股股份,总额约105.32万港元
港股异动 | 丹诺医药-B(06872.HK)午后飙升16% TNP-2092治疗人工关节感染IIb期试验完成首例入组
智通财经 · 10-27
港股异动 | 丹诺医药-B(06872.HK)午后飙升16% TNP-2092治疗人工关节感染IIb期试验完成首例入组
港股异动 | 丹诺医药-B(06872)午后飙升16% TNP-2092治疗人工关节感染IIb期试验完成首例入组
智通财经 · 10-27
港股异动 | 丹诺医药-B(06872)午后飙升16% TNP-2092治疗人工关节感染IIb期试验完成首例入组
丹诺医药-B(06872)拟回购不超过5000万元的H股
智通财经 · 10-26
丹诺医药-B(06872)拟回购不超过5000万元的H股
丹诺医药-B(06872)第二次临时股东会通过H股激励计划、回购授权及章程修订
公告速递 · 10-23
丹诺医药-B(06872)第二次临时股东会通过H股激励计划、回购授权及章程修订
加载更多
公司概况
公司名称:
丹诺医药-B
所属市场:
SEHK
上市日期:
--
主营业务:
丹诺医药(苏州)股份有限公司(原名:丹诺医药(苏州)有限公司)是一家主要从事发现、开发及商业化差异化的创新药产品的中国公司。该公司的产品主要包括用于治疗幽门螺杆菌的新分子实体候选药物利福特尼唑(TNP-2198)、用于治疗植入体相关细菌感染的三靶点抗菌候选药物利福喹酮(TNP-2092)注射剂、用于治疗肠道菌群代谢相关疾病的多靶点抗菌候选药物TNP-2092口服制剂、化学系列小分子TNBi-1、多靶点偶联药物系列TNBi-2以及化学系列双功能小分子TNBm-1。该公司专注于细菌感染和代谢相关疾病领域。
发行价格:
--
{"stockData":{"symbol":"06872","market":"HK","secType":"STK","nameCN":"丹诺医药-B","latestPrice":73.3,"timestamp":1795162107713,"preClose":74.5,"halted":0,"volume":51050,"delay":0,"changeRate":-0.016107382550335607,"floatShares":52303800,"shares":52303800,"eps":-3.845134,"marketStatus":"休市中","change":-1.2,"latestTime":"11-20 16:08:27","open":76.35,"high":78.8,"low":72.1,"amount":3833427,"amplitude":0.089933,"askPrice":73.3,"askSize":300,"bidPrice":72.3,"bidSize":250,"shortable":0,"etf":0,"ttmEps":-3.065,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795397400000},"marketStatusCode":7,"adr":0,"listingDate":1779379200000,"exchange":"SEHK","adjPreClose":74.5,"openAndCloseTimeList":[[1795138200000,1795147200000],[1795150800000,1795161600000]],"volumeRatio":0.9134013259904841,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06872","defaultTab":"news","newsList":[{"id":"2684952864","title":"港股异动 | 丹诺医药-B(06872)涨近3% 近日与远大生命科学订立独家商业化合作协议补充协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2684952864","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684952864?lang=zh_cn&edition=full","pubTime":"2026-11-18 13:45","pubTimestamp":1794980755,"startTime":"0","endTime":"0","summary":"消息面上,丹诺医药-B发布公告,公司始终积极推进利福特尼唑首个适应症的中国上市许可审批流程及相应的商业化筹备工作。为配合相关审评进程、确保合作安排与利福特尼唑的预期商业化时间表保持一致,并进一步巩固公司与远大生命科学之间的长期合作关系,董事会欣然宣布,于2026年11月12日,公司与远大生命科学订立了合作协议补充协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1524868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872","BK1161","KCAI","BK4585","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684528629","title":"港股异动 | 丹诺医药-B(06872.HK)涨近3% 近日与远大生命科学订立独家商业化合作协议补充协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2684528629","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684528629?lang=zh_cn&edition=full","pubTime":"2026-11-18 13:45","pubTimestamp":1794980755,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683825574","title":"丹诺医药-B(06872)与远大生命科学订立独家商业化合作协议补充协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2683825574","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683825574?lang=zh_cn&edition=full","pubTime":"2026-11-13 18:39","pubTimestamp":1794566397,"startTime":"0","endTime":"0","summary":"为配合相关审评进程、确保合作安排与利福特尼唑的预期商业化时间表保持一致,并进一步巩固公司与远大生命科学之间的长期合作关系,董事会欣然宣布,于2026年11月12日,公司与远大生命科学订立了合作协议补充协议,据此,双方同意将合作协议项下有关远大生命科学因公司未能于指定日期前获得利福特尼唑首个适应症的中国上市许可而有权通过书面通知单方面终止合作协议的相关期限,由2026年12月31日延长至2027年7月31日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139395683","title":"丹诺医药-B(06872)与远大生命科学签署补充协议 将TNP-2198中国上市许可里程碑延后至2027年7月31日","url":"https://stock-news.laohu8.com/highlight/detail?id=1139395683","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139395683?lang=zh_cn&edition=full","pubTime":"2026-11-13 18:20","pubTimestamp":1794565234,"startTime":"0","endTime":"0","summary":"丹诺医药-B(06872)11月13日发布自愿公告称,已于2026年11月12日与远大生命科学订立《独家商业化合作协议补充协议》。双方同意,将原协议中“若丹诺医药未能于2026年12月31日前获得TNP-2198首个适应症中国上市许可,远大生命科学有权单方面终止合作”的期限,延长至2027年7月31日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121653491","title":"丹诺医药-B(06872)公布两大核心抗感染新药最新研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1121653491","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121653491?lang=zh_cn&edition=full","pubTime":"2026-11-12 16:46","pubTimestamp":1794473199,"startTime":"0","endTime":"0","summary":"2026年11月12日,丹诺医药(苏州)股份有限公司发布自愿公告,披露其两款核心产品利福特尼唑及利福喹酮的最新研发里程碑,为股东及潜在投资者提供业务最新进展信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112575247","title":"丹诺医药-B回购4000股股份,总额约28.09万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1112575247","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112575247?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:46","pubTimestamp":1793871973,"startTime":"0","endTime":"0","summary":"丹诺医药(苏州)股份有限公司于2026年11月5日发布翌日报表,披露当天在香港联合交易所场内回购4000股H股。该批股份占回购前公司已发行股本的约0.007647%,回购价格介乎每股68.8港元至71.6港元,合计耗资约28.09万港元。根据公告,回购完成后,丹诺医药-B已发行股本由52230776股变动至52203776股,同时库存股数量增至25150股,均为H股。公告还显示,公司已确认此次回购活动经过董事会正式批准,并遵守香港联合交易所证券上市规则及其他相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丹诺医药-B回购4000股股份,总额约28.09万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110750332","title":"丹诺医药-B:11月4日回购5000股,耗资约34.05万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110750332","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110750332?lang=zh_cn&edition=full","pubTime":"2026-11-04 18:16","pubTimestamp":1793787382,"startTime":"0","endTime":"0","summary":"丹诺医药(苏州)股份有限公司于2026年11月4日公告,当天在香港联合交易所场内回购5000股H股,约占回购前已发行股本的0.009558%,每股回购价介乎64.70港元至69.60港元,合计支付约34.05万港元。根据公告,购回授权于2026年10月23日获股东大会批准,授权公司可回购的股份总数为5,232,892股,截至本次回购,公司已累计回购21,150股,占授权获得当日已发行股本的约0.040417%。公司确认本次股份购回已遵守香港联合交易所有限公司证券上市规则及相关法律法规的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"丹诺医药-B:11月4日回购5000股,耗资约34.05万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680703104","title":"丹诺医药-B(06872.HK)11月4日斥资34.05万港元回购5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680703104","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680703104?lang=zh_cn&edition=full","pubTime":"2026-11-04 18:08","pubTimestamp":1793786912,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135446496","title":"丹诺医药-B回购5000股股份,涉资约32.20万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135446496","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135446496?lang=zh_cn&edition=full","pubTime":"2026-11-03 18:16","pubTimestamp":1793700999,"startTime":"0","endTime":"0","summary":"丹诺医药(苏州)股份有限公司于2026年11月3日发布公告,披露其在香港联合交易所场内进行股份回购等事项。公告显示,丹诺医药-B于2026年11月3日回购股份5000股,占回购前公司已发行股本的约0.009557%。本次回购价格介乎每股63.10港元至65.40港元,合计耗资约32.20万港元。公司方面称,上述操作依据2026年10月23日通过的股份回购授权进行,授权额度为5,232,892股,截至目前已回购16,150股,占授权通过当日已发行股本约0.030862%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"丹诺医药-B回购5000股股份,涉资约32.20万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680775741","title":"丹诺医药-B(06872)11月3日斥资32.2万港元回购5000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680775741","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680775741?lang=zh_cn&edition=full","pubTime":"2026-11-03 18:05","pubTimestamp":1793700305,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丹诺医药-B(06872)发布公告,于2026年11月3日该公司斥资32.2万港元回购5000股,回购价格为每股63.1-65.4港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680136127","title":"港股异动 | 丹诺医药-B(06872)盘中涨超7% TNP-2092优先开发关节腔内注射给药治疗人工关节感染适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2680136127","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680136127?lang=zh_cn&edition=full","pubTime":"2026-11-03 10:47","pubTimestamp":1793674050,"startTime":"0","endTime":"0","summary":"消息面上,10月30日,丹诺医药-B发布公告,经综合考虑在研新药候选物利福喹酮 已有的临床数据、未被满足临床需求、竞争格局及商业潜力,本公司已选定通过关节腔内注射给药治疗人工关节感染作为利福喹酮的核心优先开发适应症。利福喹酮通过关节腔内注射给药治疗PJI,替代手术的IIa期概念验证临床试验取得积极结果,多中心IIb期临床试验亦已完成首例患者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872","BK4585","VXUS","KCAI","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193222678","title":"丹诺医药-B2026年10月股份变动月报表,股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1193222678","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193222678?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:06","pubTimestamp":1793617575,"startTime":"0","endTime":"0","summary":"丹诺医药(苏州)股份有限公司于2026年11月2日发布截至2026年10月31日的股份变动月报表。公告显示,公司本月已发行股本总额未发生变化,仍为52,328,926股。公司于2026年10月23日购回上述11,150股,并将其作为库藏股份持有,暂未予以注销。公司在公告中进一步强调,所有股份变动均经过董事会正式授权并严格遵守香港联交所《上市规则》及相关法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679686572","title":"丹诺医药-B(06872):利福喹酮(TNP-2092)优先开发关节腔内注射给药治疗人工关节感染适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2679686572","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679686572?lang=zh_cn&edition=full","pubTime":"2026-10-30 12:18","pubTimestamp":1793333924,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丹诺医药-B 发布公告,经综合考虑在研新药候选物利福喹酮 已有的临床数据、未被满足临床需求、竞争格局及商业潜力,本公司已选定通过关节腔内注射给药治疗人工关节感染作为利福喹酮的核心优先开发适应症。作为本集团核心管线,利福喹酮拥有多适应症应用前景。利福喹酮通过关节腔内注射给药治疗PJI,替代手术的IIa期概念验证临床试验取得积极结果,多中心IIb 期临床试验亦已完成首例患者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154431111","title":"丹诺医药-B(06872)将利福喹酮确定为优先开发关节腔内注射治疗人工关节感染核心适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1154431111","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154431111?lang=zh_cn&edition=full","pubTime":"2026-10-30 12:11","pubTimestamp":1793333484,"startTime":"0","endTime":"0","summary":"10月30日,丹诺医药(苏州)股份有限公司发布自愿公告,宣布已将在研新药候选物利福喹酮的核心优先开发方向确立为“关节腔内注射治疗人工关节感染”。公司称,此决定系综合考量已有临床数据、未被满足的医疗需求、竞争格局及商业潜力后作出。公司提醒投资者,药物研发存在不确定性,利福喹酮最终能否成功上市尚待进一步验证。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678177715","title":"丹诺医药-B(06872)10月27日斥资约105.32万港元回购约1.12万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678177715","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678177715?lang=zh_cn&edition=full","pubTime":"2026-10-27 20:27","pubTimestamp":1793104063,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丹诺医药-B(06872)发布公告,于2026年10月27日该公司斥资约105.32万港元回购约1.12万股,回购价格为每股83.55至108港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166827484","title":"丹诺医药-B回购11,150股股份,总额约105.32万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166827484","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166827484?lang=zh_cn&edition=full","pubTime":"2026-10-27 20:26","pubTimestamp":1793103968,"startTime":"0","endTime":"0","summary":"丹诺医药(苏州)股份有限公司于2026年10月27日发布公告,披露在香港联交所场内回购股份的情况。本次回购股份数量为11,150股,占此前已发行股本52,328,926股的约0.021308%,每股价格介乎83.55港元至108港元,累计支付约105.32万港元。根据公告,此次回购于2026年10月23日获公司批准,可回购股份的授权总量为5,232,892股,目前尚余可回购额度为5,221,742股。公司确认,本次交易已遵守香港联交所证券上市规则及相关法律法规,并由董事会正式授权。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"丹诺医药-B回购11,150股股份,总额约105.32万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678549147","title":"港股异动 | 丹诺医药-B(06872.HK)午后飙升16% TNP-2092治疗人工关节感染IIb期试验完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2678549147","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678549147?lang=zh_cn&edition=full","pubTime":"2026-10-27 13:51","pubTimestamp":1793080298,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678147542","title":"港股异动 | 丹诺医药-B(06872)午后飙升16% TNP-2092治疗人工关节感染IIb期试验完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2678147542","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678147542?lang=zh_cn&edition=full","pubTime":"2026-10-27 13:51","pubTimestamp":1793080298,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,丹诺医药-B午后飙升16%。截至发稿,涨4.71%,报97.8港元,成交额2392.77万港元。消息面上,丹诺医药在研新药候选物利福喹酮通过关节腔内注射给药治疗人工关节感染的多中心IIb期临床试验已完成首例患者入组。值得注意的是,丹诺医药公告,公司董事会已获授予购回公司股份的一般性授权,可购回的股份最高数目不超过523.29万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK4585","BK4588","06872","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678659861","title":"丹诺医药-B(06872)拟回购不超过5000万元的H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678659861","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678659861?lang=zh_cn&edition=full","pubTime":"2026-10-26 17:03","pubTimestamp":1793005427,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丹诺医药-B(06872)公布,鉴于目前H股的市场价格未能充分反映公司的内在价值及业务发展前景,董事会拟根据购回授权行使其权力。经董事会批准,公司将根据市场状况不时于公开市场购回H股,购回总金额不超过人民币5000万元。公司将以自有资金拨付H股购回计划所需资金。董事会相信,在目前市场情况下进行H股购回将表明公司对其自身业务展望及前景的信心,最终将使公司受益,并为股东创造价值。实施H股购回计划将不会对公司的财务状况或其日常业务过程造成重大不利影响。因此,董事会认为实施H股购回计划符合公司及股东的整体利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133573195","title":"丹诺医药-B(06872)第二次临时股东会通过H股激励计划、回购授权及章程修订","url":"https://stock-news.laohu8.com/highlight/detail?id=1133573195","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133573195?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:40","pubTimestamp":1792755635,"startTime":"0","endTime":"0","summary":"丹諾醫藥(蘇州)股份有限公司于2026年10月23日召开2026年第二次临时股东会。会议以投票方式表决全部议案,出席及授权代表共计30,384,754股有表决权股份,占公司已发行52,328,926股H股的58.06%。会议由董事会主席马振坤博士主持。因赞成票超过三分之二,该议案获通过。据公告披露,会议无任何股东须根据香港联交所上市规则第13.40条放弃表决或投票,也无股东提前表示反对或弃权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tennortherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0532},{"period":"1month","weight":-0.2721},{"period":"3month","weight":-0.63},{"period":"6month","weight":-0.6526},{"period":"1year","weight":-0.0317},{"period":"ytd","weight":-0.0317}],"compareEarnings":[{"period":"1week","weight":-0.0519},{"period":"1month","weight":-0.0525},{"period":"3month","weight":-0.1384},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.1326},{"period":"ytd","weight":-0.1256}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"丹诺医药(苏州)股份有限公司(原名:丹诺医药(苏州)有限公司)是一家主要从事发现、开发及商业化差异化的创新药产品的中国公司。该公司的产品主要包括用于治疗幽门螺杆菌的新分子实体候选药物利福特尼唑(TNP-2198)、用于治疗植入体相关细菌感染的三靶点抗菌候选药物利福喹酮(TNP-2092)注射剂、用于治疗肠道菌群代谢相关疾病的多靶点抗菌候选药物TNP-2092口服制剂、化学系列小分子TNBi-1、多靶点偶联药物系列TNBi-2以及化学系列双功能小分子TNBm-1。该公司专注于细菌感染和代谢相关疾病领域。","exchange":"SEHK","name":"丹诺医药-B","nameEN":"TENNOR THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丹诺医药-B(06872)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丹诺医药-B,06872,丹诺医药-B股票,丹诺医药-B股票老虎,丹诺医药-B股票老虎国际,丹诺医药-B行情,丹诺医药-B股票行情,丹诺医药-B股价,丹诺医药-B股市,丹诺医药-B股票价格,丹诺医药-B股票交易,丹诺医药-B股票购买,丹诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丹诺医药-B(06872)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}